Director, Financial Planning & Analysis; R&D

About Stoke

Stoke Therapeutics (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Using Stoke’s proprietary approach, the company is developing antisense oligonucleotides (ASOs) to selectively restore naturally occurring protein levels. Stoke’s first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome and is currently being evaluated in a Phase 3 study.

Stoke entered into a strategic collaboration with Biogen in 2025 to develop and commercialize zorevunersen for Dravet syndrome. Under the collaboration, Stoke retains exclusive rights for zorevunersen in the United States, Canada, and Mexico;
Biogen receives exclusive rest of world commercialization rights.

STK-002 is Stoke’s proprietary antisense oligonucleotide (ASO) in clinical development for the treatment of autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder. STK-002 has been granted orphan drug designation by the FDA. A Phase 1 study (OSPREY) of STK-002 in people with ADOA is now underway. The company is also conducting early research in Syngap1, a severe and rare neurodevelopmental disorder, in collaboration with Acadia Pharmaceuticals.

Stoke’s initial focus is on diseases of the central nervous system and the eye that are caused by a loss of ~50% of normal protein levels (haploinsufficiency). Proof of concept has been demonstrated in other organs, tissues, and systems, supporting broad potential for the company's proprietary approach.

The Director, Financial Planning & Analysis (R&D) will play a critical role in financial and strategic decision making at the Company, playing a key role in the future growth of the organization. The focus of this position will be to provide overall financial business partnering to the Research & Development (R&D) functions including leading the budgeting, forecasting and long-range planning processes, supporting the monthly and quarterly close process, providing monthly reporting to department leads and the Executive Leadership Team, supporting external collaborations, and performing ad-hoc financial analysis.

This person will work closely with team members, department heads and program teams to understand and manage the performance of their respective areas. In addition to supporting internal business partners, this individual will provide financial support, including reporting, budgeting, and invoicing for external collaborations. This individual will contribute to routine updates of the Company’s internal financial model. S/he will provide financial consulting and strategic support to senior management including assisting in the preparation of board presentations, financial presentations, new business opportunities, acquisition analysis and other projects requested by senior management and the Board of Directors.

The position reports to the VP, Financial Planning & Analysis.

• Develop and own the annual budgeting and quarterly reforecasting process for R&D departments.
• Support month-end close activities, including accruals, variance analysis, and issue resolution and partner with Accounting to ensure alignment between planning, reporting, and actual results.
• Develop and prepare monthly and quarterly financial reporting packages to department leads and executive leadership providing insights into financial performance, and facilitating forward-looking decision making.
• Provide support to program teams to enable program-level decision making and develop recommendations for ELT consideration.
• Lead financial oversight of clinical programs and partner with Clinical Development Operations on cost modeling for ongoing and planned studies and financial management of key vendors (e.g., CRO).
• Oversee financial processes including contract reviews, and purchase order management.
• Support external collaborations providing quarterly reporting, annual (and ad hoc) budget updates, and quarterly (and ad hoc) governance meetings.

• Develop and own the annual budgeting and…